Abstract 492P
Background
Surgery is one of the necessary treatment methods for breast cancer patients. However, wound caused by surgery is the main source of clinically related stress stimulation, and can promote tumor metastasis. Currently, as an important component of the tumor microenvironment, myeloid-derived suppressor cells (MDSC) have become a hotspot in the study of tumor metastasis.
Methods
We comprehensively explored the influence of wound stress on tumor growth, EMT related metastasis, and the recruitment of MDSC in the tumor microenvironment in a subcutaneous 4T1 tumor model.
Results
We found that wound stress stimulation promoted breast cancer growth and lung metastasis in mice, and enhanced the recruitment of stressed MDSC in the tumor microenvironment. The expression of Vimentin increased, suggesting EMT transformation. In vitro, bone marrow MDSC cells from mice undertaking stress stimulation promoted the EMT transformation in 4T1. The exosomes were extracted and the expression of mmu-miR-126a-5p was low in stressed MDSC exosomes. Mmu-miR-126a-5p overexpression suppressed tumor growth, lung metastasis and EMT transformation. Through the database screening of the target gene of mmu-miR-126a-5p combined with the results of sequencing analysis, CXCL12 was predicted to be the target gene of mmu-miR-126a-5p, which was verified by double luciferase reporting assay. CXCL12 and CXCR4 were highly expressed in the wound stress stimulation model, indicating mmu-miR-126a-5p induces breast cancer EMT transformation by targeting CXCL12/CXCR4 axis.
Conclusions
Here, we found that surgical stress stimulation can elicit the recruitment of stressed MDSC in the tumor microenvironment. Reduced exosome miR-126a-5p released by stressed MDSC leads to EMT transformation of tumor cells by attenuating the inhibition of CXCL12/CXCR4 axis in 4T1 cells and ultimately promotes increased lung metastasis. From the perspective of tumor microenvironment, these findings explain the phenomenon of increased lung metastasis caused by surgical stress stimulation and optimize new targets for MDSC, thus providing new ideas for breast cancer treatment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1288P - Neoadjuvant therapy with anti-PD-1/PD-L1 plus platinum-base chemotherapy for resectable stage II-III non-small cell lung cancer: A systematic review and meta-analysis of randomized clinical trials
Presenter: Maria Dacoregio
Session: Poster session 04
1289TiP - LANTERN study: A multi-omics digital human avatar for integrating precision medicine into clinical practice for lung cancer patients
Presenter: Emilio Bria
Session: Poster session 04
1294P - A final analysis of a phase II study of durvalumab immediately after completion of chemoradiotherapy in unresectable stage III non–small-cell lung cancer: TORG1937 (DATE study)
Presenter: Tetsuro Kondo
Session: Poster session 04
1296P - Neoadjuvant camrelizumab and apatinib in patients with resectable non-small-cell lung cancer: One-year update from a phase II trial
Presenter: Wei Guo
Session: Poster session 04
1297P - An open-label, prospective phase II study of tislelizumab in combination with chidamide as consolidation therapy in locally advanced, unresectable, stage III NSCLC
Presenter: Yi Hu
Session: Poster session 04
1298P - Chemotherapy with concurrent proton vs. photon radiotherapy in stage III NSCLC: Effects on hematological toxicity and immune therapy
Presenter: Francesco Cortiula
Session: Poster session 04
1299P - The role of radiotherapy in extensive-stage small cell lung cancer after durvalumab-based immunochemotherapy: A retrospective study
Presenter: Lingjuan Chen
Session: Poster session 04
1300P - Treatment and clinical outcome in recurrent/refractory locally advanced NSCLC following chemoradiotherapy and consolidative durvalumab
Presenter: Georg Evers
Session: Poster session 04